The study was conducted at a high-volume academic tertiary centre that specializes in the treatment of prosthetic joint infections, a complication that affects a small but meaningful fraction of the growing population of patients living with artificial joints. The researchers reviewed the records of 100 patients who underwent DAIR for acute infections of total hip replacements between 2008 and 2021, each with a minimum of two years of follow-up. Acute infections were defined using the 2018 criteria of the Musculoskeletal Infection Society, and included both infections occurring within six weeks of the original hip operation and sudden hematogenous infections, in which bacteria travel through the bloodstream and seed the implant after a symptom-free period. The average age of the patients was nearly 69 years, and more than half were women.

DAIR is the least invasive surgical option for an acute prosthetic joint infection. Rather than removing the entire implant — as required in single- or two-stage revision surgery — surgeons open the joint, thoroughly wash out the infected tissue with at least six litres of saline, exchange the modular components that bacteria can colonize, and then treat the patient with targeted antibiotics. Compared with full revision, DAIR carries less morbidity, costs less, and is technically simpler. But its Achilles heel is the biofilm: once bacteria have built a mature, protective layer on the metal and plastic surfaces of the implant, neither the immune system nor systemic antibiotics can reliably eradicate them, and the only cure is to remove the hardware entirely.

That biological reality is what makes timing so critical. Preclinical work has shown that immature Staphylococcus aureus biofilms can begin forming on implant surfaces as early as three hours after bacterial attachment, and that mature biofilms can develop within 24 hours. Although those laboratory timelines have not been directly translated to patients, they provide a sobering backdrop for the clinical data. Previous studies had already shown that in infected knee replacements, delays of more than 48 hours from admission to DAIR were associated with higher rates of septic reoperation and postoperative complications. In hip fracture care, too, surgery within 48 hours of admission is a well-established benchmark for reducing death and complications. What remained unknown was whether the same clock governed infected hip replacements.

The answer, according to the new analysis, appears to be yes. The mean time from hospital admission to DAIR in the cohort was 46.4 hours, with a wide spread ranging from 3 to 240 hours, and 27 percent of patients waited more than two days for surgery. Using multivariate regression to untangle the effects of age, health status, infection severity, and other variables, the researchers found that each additional hour of delay from admission to the operating room was associated with roughly a 2 percent increase in the odds of death within 90 days — an odds ratio of 1.02 with a confidence interval of 1.00 to 1.03 and a p-value of 0.04. Notably, the time from the onset of symptoms to surgery showed no significant relationship with any outcome, a finding the authors attribute to the inherent subjectivity and unreliability of patient-reported symptom timelines.

The study also identified other, less modifiable risk factors that shaped patient fates. Increasing age raised the risk of death within one year, with each additional year of life corresponding to a 6 percent increase in odds. Patients classified as McPherson host grade C — those with the poorest overall systemic health — faced dramatically elevated risks compared with grade A patients: a nearly thirteenfold increase in one-year mortality and a more than sevenfold increase in postoperative complications. Low preoperative haemoglobin emerged as a significant predictor of reoperation, with each gram-per-litre decrease raising the odds by about 4 percent. The severity of the local extremity condition also mattered, with grade II extremities carrying more than three times the risk of complications compared with grade I.

The raw outcomes of the cohort were sobering. Just over half of the patients — 52 percent — eventually required reoperation for stubborn infection that DAIR could not cure, and patients averaged 1.5 additional hip surgeries after the initial procedure. Thirty percent were readmitted within 90 days, and mortality reached 3 percent at 30 days, 6 percent at 90 days, and 12 percent at one year. Nearly 70 percent experienced postoperative complications, the vast majority of them severe enough to require surgical intervention. The authors caution that their centre is a regional referral hub for the most complex prosthetic joint infections, which likely inflates these failure rates compared with the 58 to 78 percent success rates reported in broader literature. Indeed, 89 percent of the cohort carried an ASA classification of III or IV, indicating severe systemic disease, and the average body mass index of 31 placed most patients in the obese category.

The microbiology added another layer of complexity. Intraoperative cultures revealed a high prevalence of difficult-to-treat pathogens, including polymicrobial infections, methicillin-resistant Staphylococcus aureus, and gram-negative organisms such as Enterococcus, Klebsiella, Enterobacter, and E. coli. Among the patients who died within a year, a quarter had polymicrobial cultures, and Enterococcus and Enterobacter species each appeared in nearly 17 percent of cases — consistent with prior research linking Enterococcus infections after hip replacement to increased mortality. Antibiotic therapy itself was a long haul: the mean initial regimen lasted 37 days, 42 percent of patients required chronic suppressive antibiotics afterwards, and the total antimicrobial exposure averaged more than 333 days per patient. Interestingly, delays beyond 48 hours did not prolong antibiotic courses, suggesting that the harm of waiting manifests through biology rather than through treatment intensity.

Perhaps the most actionable part of the study is its dissection of why delays happen. The mean time from admission to DAIR was about 6.6 hours longer than in a comparable knee infection cohort from the same institution, and the reasons for the longest delays included operating room availability, the need to optimize medical comorbidities, and the management of anticoagulant medications. Many of these barriers are modifiable. Patients on direct oral anticoagulants or warfarin typically wait days for their blood to thin back to a safe range, but reversal agents could be deployed earlier in time-critical infections. Surgeon availability and familiarity with the procedure also contributed, pointing to the value of streamlined protocols, better resource allocation, and clear institutional pathways to the operating suite.

The authors are careful to acknowledge the limits of their work. The retrospective design introduces selection bias, the single-centre cohort of 100 patients produced wide confidence intervals for some estimates, and the 13-year study window spanned changes in electronic records, surgical technique, and implant technology. The study also could not define a precise cutoff — such as the 48-hour benchmark established in knee and hip fracture care — beyond which outcomes deteriorate. Still, the central message is difficult to ignore: in infected hip replacements, the time between admission and surgery is an objective, measurable, and modifiable factor tied to survival. For hospitals, the implication is that prosthetic joint infections deserve the same urgency as hip fractures, with rapid access to the operating room treated not as a convenience but as a clinical imperative. For patients and their families, the takeaway is simpler still — when an artificial joint becomes infected, hours matter.

Subject of Research: The effect of timing from hospital admission to DAIR surgery on mortality and outcomes in acute total hip prosthetic joint infections

Article Title: Timing from admission to debridement, antibiotic, and implant retention (DAIR) affects mortality risk in total hip prosthetic joint infections

Article References: Legler, J., Morgan, S., Beaulé, P., Abdelbary, H., Grammatopoulos, G., & Garceau, S. (2026). Timing from admission to debridement, antibiotic, and implant retention (DAIR) affects mortality risk in total hip prosthetic joint infections. Journal of Bone and Joint Infection, 11(4), 463-477. https://doi.org/10.5194/jbji-11-463-2026

Image Credits: AI Generated

DOI: 10.5194/jbji-11-463-2026

Keywords: prosthetic joint infection, total hip arthroplasty, DAIR, surgical timing, mortality, biofilm, debridement, antibiotics, implant retention, reoperation, orthopaedic surgery, tertiary referral centre

The research, led by Zhuo Han and Nan Wang of Tangdu Hospital at the Fourth Military Medical University together with colleagues from Beijing Chaoyang Hospital and Xijing Hospital, analyzed 154 patients with obstructive colorectal cancer treated between 2011 and 2025. Ninety-three patients received a self-expandable metal stent followed by neoadjuvant therapy, while 61 underwent stent placement alone before surgery. Because treatment practices evolved dramatically over the fourteen-year enrollment window, the investigators stratified their analysis into two eras, 2011 to 2020 and 2021 to 2025, to separate the effects of the combined strategy from the effects of technological progress.

The biological rationale behind the combined approach is rooted in the peculiar hostility of the obstructed bowel. Compared with non-obstructive colorectal cancer, obstructed tumors are more often left-sided, larger, more poorly differentiated, and diagnosed at more advanced stages, with a greater tendency toward peritoneal spread. Obstruction also drives a cascade of systemic problems: elevated inflammatory markers such as C-reactive protein and interleukin-6, hypoproteinemia and malnutrition, and reduced physical activity that accelerates muscle loss and frailty. Recent molecular work has even identified distinct features of the obstructed tumor microenvironment, including altered extracellular matrix stiffness, activated cancer-associated fibroblasts, and a dense infiltration of CD8-positive T cells that paradoxically correlates with worse prognosis.

Emergency surgery for these patients carries perioperative mortality rates as high as 10 to 15 percent, along with elevated risks of anastomotic leakage, wound infection, and permanent stoma formation. Self-expandable metal stents, introduced in the 1990s, offered a minimally invasive alternative: an endoscopist deploys a mesh tube across the tumor, restoring bowel continuity within hours and converting an emergency into an elective operation. Meta-analyses have shown lower early complication rates, lower mortality, and far fewer stomas with stenting compared with emergency surgery. Yet long-term oncological concerns persisted, most notably a prospective study reporting significantly higher local recurrence after stenting, possibly linked to microperforations or mechanical manipulation of the tumor releasing circulating tumor DNA.

The new study addresses those concerns by layering neoadjuvant therapy onto the stent pathway. After decompression, multidisciplinary teams at each center assessed patients for systemic treatment based on locally advanced disease, molecular subtype, resectability, and performance status. Regimens ranged from XELOX and FOLFOX chemotherapy to combinations with cetuximab for RAS and BRAF wild-type left-sided tumors, and immunotherapy for patients with microsatellite instability-high or mismatch repair-deficient tumors. The theory is that decompression first reduces bowel wall edema and peritumoral inflammation, creating a healthier substrate for treatment and surgery, while neoadjuvant drugs shrink the tumor, downstage nodal disease, and potentially eradicate micrometastases.

The short-term surgical results were striking. In the 2011 to 2020 cohort, the stent-plus-therapy group had an intraoperative stoma rate of 8.6 percent versus 29.0 percent for stent alone, and postoperative complications of 8.6 percent versus 29.0 percent, both statistically significant differences. These advantages persisted into the 2021 to 2025 period. The authors attribute this to a synergistic mechanism: stent-induced decompression resolves intestinal wall edema and restores blood supply, converting lesions once deemed unsuitable for safe anastomosis into ones where primary reconstruction is feasible, while neoadjuvant therapy further reduces tumor volume and inflammation. Avoiding a stoma carries profound quality-of-life implications, with longitudinal data showing that ostomy patients suffer persistent deficits in physical, emotional, and social functioning for up to a year after surgery.

Pathological outcomes told an equally compelling story about the modern era. In the 2021 to 2025 cohort, 20.7 percent of neoadjuvant-treated patients achieved major tumor regression, graded as Tumor Regression Grade 0 to 1, and rates of T and N downstaging reached 39.7 percent and 60.3 percent respectively, far exceeding the earlier period when regimens consisted mainly of standard chemotherapy alone. The contemporary group also showed significantly fewer positive lymph nodes and significant improvements in pathological T and N stages. The authors link this enhanced response to the evolution of neoadjuvant regimens, including targeted and immune-based combinations that act on both the primary tumor and micrometastatic disease.

Survival analysis revealed a nuanced picture. In the earlier cohort, the neoadjuvant group showed marginally better three- and five-year disease-free and overall survival, but the differences did not reach statistical significance. In the 2021 to 2025 cohort, however, the combined strategy was associated with a statistically significant improvement in overall survival, with a reported P value of 0.013, while disease-free survival had not yet diverged, possibly because follow-up in that cohort remains short at a median of 41.3 months. The authors caution that retrospective design, modest sample size, and the absence of propensity score matching limit causal inference, but the consistency of surgical and pathological benefits across both eras strengthens the overall signal.

Perhaps the most practice-changing finding concerns timing. For patients treated with a stent alone, an interval of 14 to 21 days between stenting and surgery was associated with significantly better overall survival, a window during which decompression restores nutrition, dampens systemic inflammation, and allows prehabilitation without giving the tumor unnecessary time to progress. For patients receiving neoadjuvant therapy, the calculus differs: intervals exceeding 90 days were associated with significantly worse disease-free survival, suggesting that systemic treatment should be completed and surgery performed within roughly three months. A nationwide Chinese survey cited in the paper found that nearly half of stenting hospitals operated within two weeks, while about a fifth waited ten to twelve weeks when neoadjuvant therapy was given, underscoring how variable current practice remains.

The study arrives as two prospective trials, OUTSTAND and NACSOC-02, work to confirm whether stent-based neoadjuvant strategies can be standardized for obstructive left-sided colorectal cancer, with the latter testing immunotherapy combinations after decompression. For now, the retrospective evidence offers a coherent clinical algorithm: decompress with a stent at an experienced center, use the restored physiological window to deliver modern systemic therapy tailored to molecular subtype, and schedule radical surgery within a defined interval, ideally before 90 days elapse. If prospective data validate these findings, the dreaded obstructed bowel, long a surgical emergency defined by rushed decisions and permanent stomas, may instead become the starting point of a carefully sequenced, multidisciplinary treatment plan that improves both survival and the daily lives of patients.

Subject of Research: Neoadjuvant therapy combined with self-expandable metal stent placement for obstructive colorectal cancer

Article Title: Comparative effectiveness of neoadjuvant therapy combined with stent placement versus stent alone in obstructive colorectal cancer: a multicenter retrospective analysis

Article References: Han, Z., Zhang, B., Liu, S., Wu, T., Qiao, Q., He, X., Han, J., & Wang, N. (2026). Comparative effectiveness of neoadjuvant therapy combined with stent placement versus stent alone in obstructive colorectal cancer: a multicenter retrospective analysis. BMC Cancer, 26(1), Article 1139. https://doi.org/10.1186/s12885-026-16728-2

Image Credits: AI Generated

DOI: 10.1186/s12885-026-16728-2

Keywords: colorectal cancer, bowel obstruction, self-expandable metal stent, neoadjuvant therapy, bridge to surgery, overall survival, disease-free survival, tumor regression grade, surgical timing, stoma, immunotherapy, retrospective study